CONDOM USE PROMOTES REGRESSION OF CERVICAL INTRAEPITHELIAL NEOPLASIA AND CLEARANCE OF HUMAN PAPILLOMAVIRUS: A RANDOMIZED CLINICAL TRIAL
|
|
- Ashley McDowell
- 5 years ago
- Views:
Transcription
1 Int. J. Cancer: 107, (2003) 2003 Wiley-Liss, Inc. Publication of the International Union Against Cancer CONDOM USE PROMOTES REGRESSION OF CERVICAL INTRAEPITHELIAL NEOPLASIA AND CLEARANCE OF HUMAN PAPILLOMAVIRUS: A RANDOMIZED CLINICAL TRIAL Cornelis J.A. HOGEWONING 1, Maaike C.G. BLEEKER 2, Adriaan J.C. VAN DEN BRULE 2, Feja J. VOORHORST 3, Peter J.F. SNIJDERS 2, Johannes BERKHOF 3, Pieter J. WESTENEND 4 and Chris J.L.M. MEIJER 2 * 1 Department of Gynaecology and Obstetrics, Albert Schweitzer Hospital, Dordrecht, the Netherlands 2 Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands 3 Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands 4 Department of Pathology, Albert Schweitzer Hospital, Dordrecht, the Netherlands Women with persistent HPV infections have increased risk of progressive CIN lesions. Transmission of HPV between sexual partners might maintain viral infection and, consequently, may influence the clinical course of CIN. We investigated the effect of condom use on regression of CIN lesions and on clearance of HPV. Women with CIN and their male sexual partners were randomized for condom use (condom group n 72 and noncondom group n 76). They were conservatively managed and followed every 3 6 months by colposcopy, cytology and HPV testing by GP5 /6 PCR. Baseline cervical biopsy specimens were taken. Median follow-up time for women was 15.2 months (range ). Outcomes of interest were clinical regression of CIN at colposcopy and clearance of HPV. Outcomes were assessed in 64 women of the condom group and 61 women of the noncondom group. Women in the condom group showed a 2-year cumulative regression rate of 53% vs. 35% in the noncondom group (p 0.03). The 2-year cumulative rates of HPV clearance were 23% vs. 4%, respectively (p 0.02). Although lower regression rates were found if women were HPV-positive and had >CIN2 lesions at baseline, effects of condom use were found both in women with CIN1 and in women with >CIN2 lesions. Condom use promotes regression of CIN lesions and clearance of HPV Wiley-Liss, Inc. Key words: cervical intraepithelial neoplasia; human papillomavirus; condom use; clinical course Persistent infection of the cervical epithelium with high-risk types of HPV plays a major role in the development, maintenance and progression of CIN. 1,2 HPV has been found in 99.7% of cervical cancers worldwide. 3 Sexual intercourse is the primary mode for transmission or acquisition of HPV, and prevalence is related to many determinants involving sexual behavior characteristics. 4 6 Case-control studies of male sexual partners of women with cervical cancer have shown a relation between male sexual behavior and cervical cancer. 7,8 The presence of HPV DNA in penile swabs conveyed a 5-fold risk of cervical cancer to their wives. 5 Studies on the risk factors of CIN supported a protective effect of condom use in women, emphasizing the venereal nature Coker et al. 12 found that among high-risk HPV-positive women longer-duration barrier method use was associated with a reduced risk of CIN. Manhart and Koutsky 13 reported in a meta-analysis that data on effects of condom use preventing HPV infection and HPV-related conditions were inconsistent. However, none of these studies was conducted explicitly to assess the effectiveness of condoms at preventing HPV infection and HPV-related conditions. Previously, we showed that flat penile lesions are associated with the presence of HPV and that regression is dependent on the presence of HPV 14 (see also Bleeker and Hogewoning, 2003, accompanying paper). Continuous transmission of HPV in sexual partners having HPV-associated genital lesions might reduce the chance of viral clearance. In a randomized clinical trial, we investigated the influence of condom use on the clinical course of HPV-associated genital lesions and HPV infection in sexual partners. In the present report, we evaluate the effects of condom use on CIN regression and HPV clearance. MATERIAL AND METHODS Study population and design Women referred to the colposcopy clinic of the Albert Schweitzer Hospital, Dordrecht, the Netherlands, from January 1995 to June 2002 were asked to bring in their male sexual partner. Eligible were women with an abnormal cervical smear (mild dysplasia or worse) and/or ccin and/or hcin. Women were evaluated for CIN by colposcopy and by histologic evaluation of cervical biopsy specimens at baseline. Cervical smears were taken for cytology and HPV testing by PCR. The outline of the study was verbally explained and written information given to couples who had no other sexual partners. Willing couples returned within 2 weeks to discuss the study protocol in detail, and additional questions were answered. Both the period of condom use, i.e., only during the study and for at least 3 months, and the instructions on condom use, i.e., during genital genital contact, were discussed with participants. Latex condoms (Durex fetherlite; Netherlands LRC, Leerdam, the Netherlands) with basic lubricant (without spermicidal and/or virus-inactivating substances) were given free, to increase study compliance. Exclusion criteria were surgical treatment of the cervical lesion and regular condom use at baseline, i.e., using condoms for birth control. CIN2 and CIN3 lesions over Abbreviations: ccin, colposcopicly cervical intraepithelial neoplasia; CI, confidence interval; CIN, cervical intraepithelial neoplasia; EIA, enzyme immunoassay; hcin, histologicly cervical intraepithelial neoplasia; HPV, human papillomavirus; HR, hazard ratio; LLETZ, large-loop biopsy of the entire transformation zone; STD, sexually transmitted disease. Grant sponsor: Dutch Prevention Fund/Zorg Onderzoek Nederland; Grant number: This work is dedicated to Jan M.M. Walboomers, who passed away on 2 February He was one of the principal investigators of this project. The first 2 authors contributed equally to this work. *Correspondence to: Department of Pathology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, the Netherlands. Fax: cjlm.meijer@vumc.nl Received 13 March 2003; Revised 1 July 2003; Accepted 18 July 2003 DOI /ijc.11474
2 812 HOGEWONING ET AL. FIGURE 1 Trial profile. 2 cervical quadrants were treated according to standard protocols. Irrespective of CIN grade at baseline, couples were randomized for condom use in blocks of 2 if conservative management of the CIN lesion was decided. Per block of 2 couples, the sequence of condom and noncondom allocation was based on a table of random numbers. Colposcopic and cervical smears were repeated after 3, 6 and 12 months and subsequently every 6 months. Condom use was verbally verified at each visit by asking the frequency of condom use failure. To minimize interference with the natural course of CIN, a biopsy specimen was taken during follow-up only when progression of CIN lesions was suspected on the basis of findings at colposcopy and/or cytology to justify the LLETZ procedure. Follow-up was ended if women were treated by LLETZ. Couples were asked to complete a questionnaire on lifestyle habits, including sexual behavior. Independently of each other and in separate rooms, questionnaires were completed. This questionnaire was introduced in The study protocol was approved by the ethics review board of the hospital (protocol CGE/95/238), and the couples signed informed consent before enrollment. Colposcopy Before colposcopic evaluation, cervical smears were taken for cytologic and HPV testing. For HPV testing, a Cervex brush (Rovers Medical Devices, Oss, the Netherlands) was used to collect cells from the cervix. The brush was placed in 5 ml of PBS solution with 0.001% thimerosal (Merthiolate) (BDH, Poole, UK), and samples were sent to the laboratory and stored at 4 C until testing. 15 Standard colposcopy was performed after application of 3% acetic acid solution and blinded of data from previous visits. Colposcopic characteristics such as acetowhiteness, mosaic, punctation, leukoplakia and atypical vessels were assessed and classified according to the international terminology. 16 Minor changes, e.g., thin acetowhite epithelium, fine mosaic, fine punctation and thin leukoplakia, were noted as ccin1 and major changes, e.g., dense acetowhite epithelium, coarse mosaic, coarse punctation and atypical vessels, as ccin2 or ccin3. Other diagnoses, e.g., squamous metaplasia, inflammatory changes, polyps or atrophic changes, were also noted. An overview of the colposcopic impression was drawn and categorized on the basis of the most atypical site: no ccin, ccin1, ccin2 and ccin3. Subsequently, colposcopic findings were documented by photographs. Photographs were reviewed by an experienced colposcopist blinded of any clinical data. In case of discrepancies ( 10%), a consensus diagnosis was made. Lesions were graded before linking these data on condom use. HPV testing Processing and testing of cervical scrapings for HPV analysis were performed as described previously at the Department of Pathology, VU University Medical Center. 15 Samples were centrifuged and cell pellets resuspended in 1,000 l TRIS buffer. In PCR tests, aliquots of 10 l were used. The quality of the specimen was tested by -globin PCR, and 14 high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and 6 low-risk (6, 11, 40, 42, 43 and 44) HPV genotypes were identified by the clinically validated HPV GP5 /6 PCR EIA. Samples negative on both the -globin and HPV PCR tests were considered inadequate and excluded. Definitions of CIN regression and HPV clearance Regression of the ccin lesion was defined as 2 consecutive no ccin diagnoses at colposcopy. Women were considered to have cleared the HPV infection when 2 consecutive negative HPV tests were obtained.
3 CONDOM USE AND CIN REGRESSION/HPV CLEARANCE 813 Statistical analysis Analyses for condom use were by intention to treat. Differences between the condom and the noncondom groups were assessed by 2 tests or independent t-tests. In survival analysis, the time point of CIN regression and HPV clearance was taken as the midpoint between the last positive and the first negative results. Kaplan- Meier curves, for regression of ccin lesions and clearance of HPV, were compared by means of 2-sided log-rank tests. Cox regression analyses were performed to calculate the HR and 95% CI, adjusted for condom use, HPV status, histologic CIN grade (either hcin1 or hcin2) and age (tertiles). HPV status was defined by the presence of HPV at baseline. HPV-positive women were stratified into HPV-16, other high-risk HPV or only low-risk HPV to assess whether CIN regression and/or HPV clearance was related to HPV type. Interaction terms were added to the Cox model to assess whether the effect of condom use was related to HPV status or the hcin grade of the lesions. Within the condom group, whether the effect was dependent on the duration of condom use was assessed. Therefore, Kaplan-Meier analyses were performed on women who still had colposcopic CIN or HPV present at 6 months and were stratified for condom use at this time point. Statistical significance was set at the 0.05 level. For statistical analyses, SPSS (Chicago, IL) version 9.0 software was used. RESULTS Characteristics of the study population The trial profile is given in Figure 1. Of 255 couples selected for the presence of CIN in the female partner, 17 were not willing to participate, 78 women were treated by LETTZ and 12 women were excluded due to regular condom use, leaving 148 women randomized (condom group n 72 and noncondom group n 76). Women were excluded because of no colposcopic CIN (n 9), no colposcopic diagnosis (n 4) or loss to follow-up (n 10). The remaining 125 women were followed: 64 in the condom group and 61 in the noncondom group. Median follow-up time was 16.4 (range ) months in the condom group and 12.8 (range ) months in the noncondom group. Median duration of condom use was 6.0 (range ) months, and failure to use condoms was reported by 7 women with a median of 2 times during the period of condom use (range 1 5). Characteristics of both groups are shown in Table I. At baseline, colposcopic diagnoses were, in the condom group, ccin1 (n 34), ccin2 (n 29) and ccin3 (n 1) and, in the noncondom group, ccin1 (n 36), ccin2 (n 24) and ccin3 (n 1). Representative histologic diagnoses of biopsy specimens were not available in 6 (9%) women of the condom group and 4 (7%) women of the noncondom group. Eight of them had ccin1 lesions and 2 had a ccin2 lesion. The remaining biopsies showed, in the condom group, no hcin in 8 (14%), hcin1 in 18 (31%), hcin2 in 31 (53%) and hcin3 in 1 (2%) and, in the noncondom group, no hcin in 11 (19%), hcin1 in 25 (44%), hcin2 in 19 (33%) and hcin3 in 2 (4%). Histologic evaluation of ccin1 lesions (n 62) showed no hcin in 13 (21%), hcin1 in 31 (50%), hcin2 in 17 (27%) and hcin3 in 1 (2%) biopsy specimens. Histologic evaluation of ccin2 lesions (n 51) showed no hcin in 6 (12%), hcin1 in 11 (22%), hcin2 in 32 (63%) and hcin3 in 2 (4%) biopsy specimens. The 2 women with ccin3 were included in the study because histologic specimens showed hcin1 and hcin2, respectively. Three women with hcin3 lesions were included because their lesions were small ( 2 cervical quadrants). At baseline, 2/64 (3%) cervical scrapes of the condom group and 2/61 (3%) cervical scrapes of the noncondom group were inadequate for HPV testing, i.e., were negative in both the -globin and HPV PCR tests. Of the remaining, 101 (84%) scrapes were positive for HPV: 54 (87%) of the condom group and 47 (80%) of the noncondom group. Of the HPV-positive women, HPV-16 was found in 27 (50%) of the condom group and in 22 (47%) of the noncondom group and other high-risk HPV (not HPV-16) was found in 26 (48%) and 22 (47%), respectively. Only FIGURE 2 Effect of condom use on regression of CIN lesions (a) and clearance of HPV (b). low-risk HPV was found in 1 (2%) HPV-positive woman of the condom group and in 3 (6%) HPV-positive women of the noncondom group. Questionnaires were obtained from 51/125 (41%) women, 26/64 (41%) of the condom group and 25/61 (41%) of the noncondom group. No statistical differences were found between the condom and noncondom groups for smoking habits, age at first sexual intercourse, number of sexual partners, number of noncondom sexual partners, history of STDs, other sexual partners last year, duration of the current relation, frequency of sexual intercourse and contraceptive use (Table I). Regression of CIN The 2-year cumulative regression rate of ccin was 53% in the condom group (n 57) vs. 35% in the noncondom group (n 51, log rank p 0.03; HR 3.1, 95% CI ) (Fig. 1, Table II). Since regression was defined as 2 consecutive no ccin diag-
4 814 HOGEWONING ET AL. TABLE I CHARACTERISTICS OF THE STUDY POPULATION Number (%) Condom group Number (%) Noncondom group Number (%) Study subjects (51) 61 (49) Age (mean, range, in years) 34.6 ( ) 34.1 ( ) 35.1 ( ) (34) 21 (33) 21 (34) (33) 23 (36) 18 (30) (34) 20 (31) 22 (36) Follow-up time (median, range, in months) 15.2 ( ) 16.4 ( ) 12.8 ( ) 0.4 HPV at baseline 0.6 Positive 101 (84) 54 (87) 47 (80) 0.3 HPV (49) 27 (50) 22 (47) 0.5 Other high-risk HPV (not HPV-16) 48 (48) 26 (48) 22 (47) Only low-risk HPV 4 (4) 1 (2) 3 (6) Negative 20 (17) 8 (13) 12 (20) ND CIN grade at colposcopy 0.3 CIN1 70 (56) 34 (53) 36 (59) CIN2 53 (42) 29 (45) 24 (39) CIN3 2 (2) 1 (2) 1 (2) CIN grade at histology 0.2 No biopsy No CIN 19 (17) 8 (14) 11 (19) CIN1 43 (37) 18 (31) 25 (44) CIN2 50 (43) 31 (53) 19 (33) CIN3 3 (3) 1 (2) 2 (4) Characteristics obtained by questionnaires Study subjects 51 (41) 26 (41) 25 (41) 1.0 Smoking 0.1 No 25 (49) 16 (62) 9 (36) Yes 26 (51) 10 (38) 16 (64) Years (mean, range) 18.7 (7 35) 17.0 (10 25) 19.5 (7 35) 0.5 Cigarettes per day (mean, range) 16.2 (2 30) 15.2 (2 30) 16.8 (5 30) 0.6 Oral contraceptive use 0.3 No 23 (45) 14 (54) 9 (36) Yes 28 (55) 12 (46) 16 (64) Age at first sexual intercourse (years, mean, range) 16.3 (13 21) 16.3 (13 21) 16.2 (13 21) 0.7 History of STD 0.4 No 45 (88) 24 (92) 21 (84) Yes 6 (12) 2 (8) 4 (16) Lifetime sexual partners Overall (mean, range) 5.9 (1 30) 5.6 (1 15) 6.3 (1 30) 0.6 Noncondom partners (mean, range) 3.9 (1 10) 4.3 (1 10) 3.6 (1 10) 0.3 Other sexual partner last year 0.5 No 49 (96) 24 (92) 25 (100) Yes 2 (4) 2 (8) 0 (0) Type of relationship 0.7 Married/living together 46 (90) 24 (92) 22 (88) Living apart 5 (10) 2 (8) 3 (12) Duration relation in years (mean/range) 9.2 (0.6 35) 9.7 (0.6 35) 8.7 (1 28) 0.7 Frequency sexual Intercourse Frequency per month (mean, range) 7.2 (0 22.5) 7.2 (0 22.5) 7.2 (1 22.5) 1.0 Frequency last month (mean, range) 5.5 (0 20) 4.6 (0 20) 6.4 (1 20) Not be determined due to samples being inadequate for HPV testing. CIN grade (at colposcopy and histology) refers to diagnoses made at baseline. p noses, 17 women were excluded due to lack of follow-up data after they showed a normal colposcopy once. Age was not related to regression of CIN in our study population. Less regression of ccin was seen in HPV-positive women (HR 0.2, 95% CI ) and in women with hcin2 at baseline (HR 0.3, 95% CI ). In HPV-positive women, regression of CIN was not related to HPV type when stratified into HPV-16, other high-risk HPV or only low-risk HPV. The effect of condom use was not related to HPV status (p 0.4) or hcin grade at baseline (p 0.8). Since the outcome variable for regression of ccin was defined by colposcopy, analyses were also performed with inclusion of the ccin grade instead of the hcin grade defined at baseline. Less regression of ccin was observed in women with ccin2 compared to women with ccin1 at baseline (HR 0.3, 95% CI , p 0.003). In women who still had ccin lesions at 6 months, no different regression rates were found during follow-up to 24 months in those who used condoms longer than 6 months (n 14) compared to those who used condoms for less than 6 months (n 15; log-rank p 0.6). Clearance of HPV The 2-year cumulative rate of HPV clearance was 23% in the condom group (n 53) vs. 4% in the noncondom group (n 38, log rank p 0.02; HR 12.1, 95% CI ) (Fig. 2, Table II). Of the 125 women, 34 were excluded in the HPV clearance analyses since they were HPV-negative at baseline (n 20), they had cervical scrapes that were inadequate for HPV testing at baseline and/or during follow-up (n 7) or there was no available follow-up data on HPV after they were HPV-negative once (n 7). No relation was found between clearance of HPV and age. Clearance of HPV was related to hcin grade; i.e., less HPV clearance was found in women with hcin2 compared to women with hcin1 at baseline (HR 0.2, 95% CI ). However, HPV clearance was not related to ccin grade at baseline (HR
5 CONDOM USE AND CIN REGRESSION/HPV CLEARANCE 815 TABLE II PROGNOSTIC FACTORS FOR CIN REGRESSION AND HPV CLEARANCE CIN regression HPV clearance Number HR (95% CI) p Number HR (95% CI) p Condom use No Yes ( ) ( ) 0.01 HPV Negative NA Positive ( ) NA HPV Other high-risk HPV (not HPV-16) ( ) ( ) 0.2 Only low-risk HPV ( ) Histologic CIN grade CIN CIN ( ) ( ) 0.02 Age (years) ( ) ( ) ( ) ( ) 0.1 Adjustments were made for all other factors in the table. NA, not applicable. 1 Could not be calculated since no clearance was observed in this category. 0.4, 95% CI ). In HPV-positive women, HPV clearance was not related to HPV type when stratified into HPV-16, other high-risk HPV or only low-risk HPV. hcin grade at baseline histology was not related to the effect of condom use on HPV clearance (p 0.9). In women who still were HPV-positive after 6 months, no different clearance rates were found in those who used condoms longer than 6 months (n 17) compared to those who used condoms for less than 6 months (n 14, log-rank p 0.6). DISCUSSION In a randomized clinical study, performed in a non-std clinic, 125 women with ccin were followed by colposcopy and HPV testing. We found that condom use promotes regression of ccin and clearance of HPV. The 2-year cumulative regression rate for ccin was 53% in the condom group vs. 35% in the noncondom group (p 0.03), and 2-year cumulative rates of HPV clearance were 23% vs. 4%, respectively (p 0.02). These beneficial effects of condom usage were independent of hcin grade. One limitation of our study was that regression of CIN was defined by colposcopy and not verified by histology. Only baseline biopsy specimens were taken for histopathologic diagnoses since repeated biopsies would interfere too much with the natural course of the CIN lesion. To minimize this potential weakness, regression of ccin was defined as disappearance of the total ccin lesion and events were scored only in women with 2 consecutive no ccin diagnoses. Our findings on concordance between the colposcopic and histopathologic diagnoses are in agreement with the positive predictive rates reported by Hopman et al. 17 They reported positive predictive rates of the colposcopic impression to be 62% for no CIN, 43% for CIN1, 59% for CIN2 and 78% for CIN3. Women with a negative HPV test at baseline showed more regression of ccin compared to women who were HPV-positive. This is in agreement with findings on the relation between HPV at baseline and cytologic regression in women with abnormal smears. 18,19 In analogy, a shorter regression time of flat penile lesions was found in the absence of HPV, as reported in the accompanying paper on male sexual partners of women with CIN. Another limitation of our study is that the number of women included is relatively small and women were not randomized by CIN grade. Compared to the noncondom group, a relatively high number of women with high-grade CIN were included in the condom group, which might result in underestimation of the effect of condoms as the grade of the CIN lesion is an important prognostic factor for the regression of CIN. 20 Analyses on the effects of condoms, however, were adjusted for the most important risk factors (i.e., CIN grade and HPV status). As characteristics of sexual behavior were collected in only 41% of women, adjustments for these factors could not be done properly. However, no differences on sex-related factors between groups were found, as one would expect given the randomized design of our study. Moreover, as data collection was time-selected, the women who filled out the questionnaires comprised a representative sample of the whole population. Therefore, we conclude that these factors did not influence our findings on condom use. Current sex-related factors, especially frequency of sexual intercourse, might be relevant to assess the effect of condom use, though no differences were found among the couples analyzed. However, failure to use condoms, as was found in the condom branch, might result in a less favorable effect of condom use on CIN regression and HPV clearance. Beneficial effects of condom use were found after a relatively short duration of use (median 6.0 months). We used a minimal duration of 3 months condom use before randomization, though the maximum duration of condom use was not defined at baseline. An attractive, though hypothetical, explanation for our findings might be that condoms interfere with continuous transmission of shed HPV between sexual partners. As a consequence, in individuals who benefit from this interference, the viral load would remain under a certain critical threshold, allowing effective virus elimination by the immune system, thereby accelerating regression of the lesion. Noninterference in these individuals would, however, result in viral load levels that are sufficiently high to safeguard viral persistence. That viral load may be an important determinant in the observed phenomena is substantiated by another study, which demonstrated that women with abnormal cytology and relatively low HPV-16 loads had an increased chance of viral clearance and cytologic regression. 21 Since the viral load appears to be proportional to the size and severity of lesions, a more marked effect of condom use is expected for smaller, less severe lesions that consequently have lower viral loads. 22 Indeed, the effect was much more pronounced for penile than for cervical lesions. The former are generally smaller and less severe and have viral loads that are 5- to 10-fold lower than in their cervical counterparts (data not shown). In contrast, individuals with high viral loads are unlikely to respond to condom use since maintenance of the lesion would not depend on exposure to virus of the partner. Because women with large and severe lesions ( ccin2 on 2 quadrants) were treated for ethical reasons, only women with relatively small lesions, having most likely lower viral load values, were selected for study. Therefore, an attractive subject of future studies may be to determine the HPV
6 816 HOGEWONING ET AL. load by quantitative PCR methods, to further understand the mechanisms underlying the effect of condom use on male and female HPV-associated lesions. In conclusion, although this is a relative small study, it demonstrates that intervention with condom use for at least 3 months can promote CIN regression and HPV clearance. Our results imply that condom use should be considered as an alternative strategy in the management of women with CIN and that the need for aggressive treatments may be reduced. Condom use should also be advised in pregnant women with CIN, in whom treatment is difficult. Whether condom use might be helpful in decreasing the number of latent HPV infections in HPV-positive cytologically normal women is currently under investigation. ACKNOWLEDGEMENTS We thank Mr. R.E. van Andel and Mrs. M.C.G.T. Verkuyten for technical assistance on HPV testing. We thank Dr. N. Muñoz of the IARC for critical reading of the manuscript and critical remarks. REFERENCES 1. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354: IARC. Monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses. vol. 64. Lyon: IARC, Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto P, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189: Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walboomers JM, Schiller JT, Bock JE, Sherman ME, Lowy DR, Meijer CJ. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001;10: Bosch FX, Castellsague X, Munoz N, de Sanjose S, Ghaffari AM, Gonzalez LC, Gili M, Izarzugaza I, Viladiu P, Navarro C, Vergara A, Ascunce N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996;88: Castellsague X, Ghaffari A, Daniel RW, Bosch FX, Munoz N, Shah KV. Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: a study in Spain and Colombia. J Infect Dis 1997;176: Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87: Castellsague X, Bosch FX, Munoz N, Meijer CJ, Shah KV, de Sanjose S, Eluf-Neto J, Ngelangel CA, Chichareaon S, Smith JS, Herrero R, Moreno V, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002;346: Ho GY, Kadish AS, Burk RD, Basu J, Palan PR, Mikhail M, Romney SL. HPV-16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer 1998;78: Kjaer SK. Risk factors for cervical neoplasia in Denmark. APMIS Suppl 1998;80: Wang PD, Lin RS. Risk factors for cervical intraepithelial neoplasia in Taiwan. Gynecol Oncol 1996;62: Coker AL, Sanders LC, Bond SM, Gerasimova T, Pirisi L. Hormonal and barrier methods of contraception, oncogenic human papillomaviruses, and cervical squamous intraepithelial lesion development. J Womens Health Gend Based Med 2001;10: Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002;29: Bleeker MC, Hogewoning CJ, van den Brule AJ, Voorhorst FJ, Van Andel RE, Risse EK, Starink TM, Meijer CJ. Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. J Am Acad Dermatol 2002;47: Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5 /GP6 -mediated PCRenzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35: Stafl A, Wilbanks GD. An international terminology of colposcopy: report of the Nomenclature Committee of the International Federation of Cervical Pathology and Colposcopy. Obstet Gynecol 1991;77: Hopman EH, Kenemans P, Helmerhorst TJ. Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. Obstet Gynecol Surv 1998;53: Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001;358: Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, van der Linden HC, Runsink AP, de Schipper FA, Meijer CJ. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001;85: Östör AG. The natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12: van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozendaal L, Nobbenhuis MA, van den Brule AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002;98: Sun CA, Lai HC, Chang CC, Neih S, Yu CP, Chu TY. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol 2001;83:95 9.
HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions
British Journal of Cancer (2005) 92, 1388 1392 All rights reserved 0007 0920/05 $30.00 www.bjcancer.com HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile
More informationInt. J. Cancer: 113, (2005) 2004 Wiley-Liss, Inc.
Int. J. Cancer: 113, 36 41 (2005) 2004 Wiley-Liss, Inc. HPV-Associated Flat Penile Lesions in Men of a Non-STD Hospital Population: Less Frequent and Smaller in Size than in Male Sexual Partners of Women
More informationThe Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationNo HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 117 August 6, 2013 HPV High Risk Screening with Genotyping Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Director, Molecular Pathology
More informationThe routine use of ZedScan within one colposcopy service in England. MC Macdonald, R Lyon, JE Palmer, JA Tidy
The routine use of ZedScan within one colposcopy service in England MC Macdonald, R Lyon, JE Palmer, JA Tidy Introduction Colposcopic impression alone has been shown to be subjective with variable rates
More informationPromoting Cervical Screening Information for Health Professionals. Cervical Cancer
Promoting Cervical Screening Information for Health Professionals Cervical Cancer PapScreen Victoria Cancer Council Victoria 1 Rathdowne St Carlton VIC 3053 Telephone: (03) 635 5147 Fax: (03) 9635 5360
More informationPapers. Abstract. Introduction. Methods
Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study Susanne
More informationThe implications of HPV immunisation on cervical screening
The implications of HPV immunisation on cervical screening Dr Maggie Cruickshank Senior Lecturer in Gynaecology Scottish Cervical Cancer Prevention Programme (SCCPP) funded by CSO Cervical screening Detects
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationHPV Epidemiology and Natural History
HPV Epidemiology and Natural History Rachel Winer, PhD, MPH Associate Professor Department of Epidemiology University of Washington School of Public Health rlw@uw.edu Human Papillomavirus (HPV) DNA virus
More informationLow grade squamous intra-epithelial lesions and human papillomavirus infection in Colombian women
British Journal of Cancer (2002) 87, 1417 1421 All rights reserved 0007 0920/02 $25.00 www.bjcancer.com Low grade squamous intra-epithelial lesions and human papillomavirus infection in Colombian women
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationThe Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus Positive, Cytologically Normal Women Over a 10-Year Period
Published Online First on October 23, 2006 as 10.1158/0008-5472.CAN-06-1057 Research Article The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus Positive, Cytologically Normal
More informationReceived 14 December 2005/Returned for modification 17 February 2006/Accepted 1 May 2006
JOURNAL OF CLINICAL MICROBIOLOGY, July 2006, p. 2428 2433 Vol. 44, No. 7 0095-1137/06/$08.00 0 doi:10.1128/jcm.02608-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. Assessment
More informationPrevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea
RESEARCH COMMUNICATION Prevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea Kidong Kim 1, Jin Ju Kim 2,3, Sun Mie
More informationOpinion: Cervical cancer a vaccine preventable disease
Opinion: Cervical cancer a vaccine preventable disease Leon Snyman Principal specialist at the Department of Obstetrics and Gynaecology, Gynaecological Oncology unit, University of Pretoria and Kalafong
More informationA systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions
British Journal of Cancer (2000) 83(5), 561 565 doi: 10.1054/ bjoc.2000.1375, available online at http://www.idealibrary.com on A systematic review of the role of human papilloma virus (HPV) testing within
More informationCytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.
Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches. Fadi W. Abdul-Karim MD MEd. Professor of Pathology. Vice chair for education. Robert Tomsich Pathology and Lab Med
More informationValidation of an automated detection platform. for use with the Roche Linear Array HPV Genotyping Test ACCEPTED SEPEHR N.
JCM Accepts, published online ahead of print on September 00 J. Clin. Microbiol. doi:./jcm.0-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationand treating joins with the top of canal). at risk for cervical carcinomas, cervix.
CERVICAL CANCER Worldwide, cervical cancer is twelfth most common and the fifth most deadly cancer in women. It affects about 16 per 100,000 women per year and kills about 9 per 100,000 per year. Cervical
More informationFREQUENCY AND RISK FACTORS OF CERVICAL Human papilloma virus INFECTION
Arch. Biol. Sci., Belgrade, 66 (4), 1653-1658, 2014 DOI:10.2298/ABS1404653M FREQUENCY AND RISK FACTORS OF CERVICAL Human papilloma virus INFECTION IN WOMEN IN MONTENEGRO GORDANA MIJOVIĆ 1, TATJANA JOVANOVIĆ
More informationThe devil is in the details
The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from
More informationScreening for Cervical Cancer. Grand Rounds 1/16/13 Meggan Linck
Screening for Cervical Cancer Grand Rounds 1/16/13 Meggan Linck Cervical Cancer Worldwide 2 nd most common and 5 th deadliest U.S. 8 th most common 80% occur in developing world Median age at diagnosis
More informationGUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED
GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED This guideline is a revised version of the guideline developed in February 2000, by the Cervical Cancer Screening Working Group. This revised version
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationAttitudes to self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening
Acta Obstetricia et Gynecologica. 2007; 86: 720 725 ORIGINAL ARTICLE Attitudes to self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationDeterminants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: A Population-based, 5-Year Follow-up Study
American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 5 Printed in U.S.A. DOI: 10.1093/aje/kwg171 Determinants of Clearance
More informationHuman papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Human papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands Mitchell S Wachtel 1,
More informationChapter 6. Submitted for publication
Chapter 6 CADM1 and MAL promoter methylation levels in hrhpv-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease Submitted for publication Mariska Bierkens
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationHPV Transmission. Rachel Winer, PhD, MPH Department of Epidemiology University of Washington
HPV Transmission Rachel Winer, PhD, MPH Department of Epidemiology University of Washington rlw@u.washington.edu Disclosure Information I have no financial relationships to disclose. Human Papillomavirus
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationPathology of the Cervix
Pathology of the Cervix Thomas C. Wright Pathology of the Cervix Topics to Consider Burden of cervical cancer 1 Invasive Cervical Cancer Cervical cancer in world Second cause of cancer death in women Leading
More information- ii - Rights c
- ii - Rights c - iii - Preface Preface to the third edition Since the first edition of the HPV Information Centre, GLOBOCAN, one of the landmark products of the International Agency for Research on Cancer
More informationHuman Papillomavirus Prevalence and Type Distribution Among 968 Women in South Korea
JOURNAL OF CANCER PREVENTION Vol. 21, No. 2, June 2016 http://crossmark.crossref.org/dialog/?doi=10.15430/jcp.2016.21.2.104&domain=pdf&date_stamp=2016-6-30 http://dx.doi.org/10.15430/jcp.2016.21.2.104
More informationHUMAN PAPILLOMAVIRUS INFECTION AND INVASIVE CERVICAL CANCER IN PARAGUAY
Int. J. Cancer: 85, 486 491 (2000) 2000 Wiley-Liss, Inc. Publication of the International Union Against Cancer HUMAN PAPILLOMAVIRUS INFECTION AND INVASIVE CERVICAL CANCER IN PARAGUAY Pedro A. ROLÓN 1,
More informationCervical Cancer Screening Update. Melissa Hartman, DO Women s Health
Cervical Cancer Screening Update Melissa Hartman, DO Women s Health Previous Cervical Cancer Screening Organization Recommendation ACS (2011) ACP (2008) NCI (2003) Age 21 or 3 years after first intercourse
More informationFocus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection
HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).
More informationNorthern Ireland cervical screening programme. Information for primary care and smear takers
Northern Ireland cervical screening programme Information for primary care and smear takers From January 2011, the Northern Ireland cervical screening programme will no longer invite women aged under 25
More informationPrevalence and determinants of HPV infection among Colombian women with normal cytology
British Journal of Cancer (2002) 87, 324 333 ª 2002 Cancer Research UK All rights reserved 0007 0920/02 $25.00 www.bjcancer.com Prevalence and determinants of HPV infection among Colombian women with normal
More informationClinical Performance of Roche COBAS 4800 HPV Test
JCM Accepts, published online ahead of print on 9 April 2014 J. Clin. Microbiol. doi:10.1128/jcm.00883-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 1 2 3 4 5 6 Clinical
More informationEarly Natural History of Incident, Type-Specific Human Papillomavirus Infections in Newly Sexually Active Young Women
Research Article Cancer Epidemiology, Biomarkers & Prevention Early Natural History of Incident, Type-Specific Human Papillomavirus Infections in Newly Sexually Active Young Women Rachel L. Winer 1, James
More informationWhat is a Pap smear?
Pap smear What is a Pap smear? A Pap smear is a test that checks for changes in the cells of your cervix. The cervix is the lower part of the uterus that opens into the vagina. Developed over forty years
More informationDevelopment and Duration of Human Papillomavirus Lesions, after Initial Infection
MAJOR ARTICLE Development and Duration of Human Papillomavirus Lesions, after Initial Infection Rachel L. Winer, 1 Nancy B. Kiviat, 2 James P. Hughes, 3 Diane E. Adam, 1 Shu-Kuang Lee, 3 Jane M. Kuypers,
More informationFocus. A case. I have no conflicts of interest. HPV Vaccination: Science and Practice. Collaborative effort with Karen Smith-McCune, MD, PhD 2/19/2010
HPV Vaccination: Science and Practice George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics Director, Colposcopy Clinic,
More informationMolecular markers for diagnosis and prognosis in cervical neoplasia Eijsink, Jasper Johannes Hendrikus
University of Groningen Molecular markers for diagnosis and prognosis in cervical neoplasia Eijsink, Jasper Johannes Hendrikus IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationScreening for the Precursors of Cervical Cancer in the Era of HPV Vaccination. Dr Stella Heley Senior Liaison Physician Victorian Cytology Service
Screening for the Precursors of Cervical Cancer in the Era of HPV Vaccination Dr Stella Heley Senior Liaison Physician Victorian Cytology Service Victorian Cytology Service Dr Stella Heley Dr Siobhan Bourke
More informationYour Colposcopy Visit
Introduction Welcome to the colposcopy clinic. This booklet tells you about. The colposcopy examination.. Tests that are done in the colposcopy clinic.. What these tests look for Take a few minutes to
More informationHPV vaccine perspectives Dr. David Prado Cohrs
HPV vaccine perspectives Dr. David Prado Cohrs Universidad Francisco Marroquín, Guatemala President of the Sexually Transmitted Diseases Committee, SLIPE Disclosure statement The presenter has received
More informationHPV-DNA Test Kit in Cervical Scrapes or
Infectious Diseases in Obstetrics and Gynecology 2:126-129 (I 994) (C) 1994 Wiley-Liss, Inc. Detection of Human Papillomavirus DNA by AffiProbe HPV-DNA Test Kit in Cervical Scrapes or Biopsies-Histopathologic
More informationCross-Sectional Comparison of an Automated Hybrid Capture 2 Assay and the Consensus GP5 /6 PCR Method in a Population-Based Cervical Screening Program
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2006, p. 3680 3685 Vol. 44, No. 10 0095-1137/06/$08.00 0 doi:10.1128/jcm.02078-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. Cross-Sectional
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationAbsolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women
Absolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women 2145 Philip E. Castle, Ph.D., M.P.H. 1 Sholom Wacholder, Ph.D. 1 Mark E. Sherman,
More informationHUMAN PAPILLOMAVIRUS INFECTION IN WOMEN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS
HUMAN PAPILLOMAVIRUS INFECTION IN WOMEN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS XIAO-WEI SUN, M.D., LOUISE KUHN, PH.D., TEDD V. ELLERBROCK, M.D., MARY ANN CHIASSON, DR.P.H., TIMOTHY J. BUSH, B.A.,
More informationFeasibility of focused ultrasound therapy for recurrent cervicitis with high-risk human papillomavirus infection
Ultrasound Obstet Gynecol 2009; 34: 590 594 Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.7357 Feasibility of focused ultrasound therapy for recurrent cervicitis
More information9/18/2008. Cervical Cancer Prevention for Adolescent Populations Garcia. Faculty disclosure. Objectives. HPV Positivity by Age (UK)
Faculty disclosure Cervical Cancer Prevention for Francisco, MD, MPH Associate Professor Obstetrics & Gynecology Mexican American Studies Public Health Francisco, MD, MPH has no financial affiliations
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationChanges in type-specific human papillomavirus load predict progression to cervical cancer
J. Cell. Mol. Med. Vol 16, No 12, 2012 pp. 3096-3104 Changes in type-specific human papillomavirus load predict progression to cervical cancer Christophe E. Depuydt a, *, Arnold M. Criel a, Ina H. Benoy
More informationShrestha P CORRESPONDENCE
NJOG 2015 Jul-Dec; 20 (2):45-49 Original Article Shrestha P 1 2 2 1 Department of Obstetrics and Gynecology, Patan Academy of Health Science, Lalitpur, 2 Department of Obstetrics and Gynecology, Tribhuvan
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationUpdate of the role of Human Papillomavirus in Head and Neck Cancer
Update of the role of Human Papillomavirus in Head and Neck Cancer 2013 International & 12 th National Head and Neck Tumour Conference Shanghai, 11 13 Oct 2013 Prof. Paul KS Chan Department of Microbiology
More informationReduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
ACTA BIOMED 2007; 78: 36-40 Mattioli 1885 O R I G I N A L A R T I C L E Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationTISSUE TUMOR MARKER EXPRESSION IN
TISSUE TUMOR MARKER EXPRESSION IN NORMAL CERVICAL TISSUE AND IN CERVICAL INTRAEPITHELIAL NEOPLASIA, FOR WOMEN WHO ARE AT HIGH RISK OF HPV (HUMAN PAPILLOMA VIRUS INFECTION). Raghad Samir MD PhD Verksamhet
More informationHe Said, She Said: HPV and the FDA. Audrey P Garrett, MD, MPH June 6, 2014
He Said, She Said: HPV and the FDA Audrey P Garrett, MD, MPH June 6, 2014 Disclosure Speaker for Merck Gardasil Speaker for Hologic Thin Prep and Cervista Cervical Cancer Screening: 21 st century Dr. Papanicolaou
More informationTreatment of Cervical Intraepithelial Neoplasia. Case. How would you manage this woman?
Treatment of Cervical Intraepithelial Neoplasia Karen Smith-McCune Professor, Department of Obstetrics, Gynecology and Reproductive Sciences I have no conflicts of interest Case How would you manage this
More informationNATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN NATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN
NATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN NATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN GLORIA Y.F. HO, PH.D., ROBERT BIERMAN, M.D., LEAH BEARDSLEY,
More informationA Prospective Study of High-Grade Cervical Neoplasia Risk Among Human Papillomavirus-Infected Women
A Prospective Study of High-Grade Cervical Neoplasia Risk Among Human Papillomavirus-Infected Women Philip E. Castle, Sholom Wacholder, Attila T. Lorincz, David R. Scott, Mark E. Sherman, Andrew G. Glass,
More informationCervical Cancer Screening - Improving PAP Rates. Objectives
Cervical Cancer Screening - Improving PAP Rates Dineo Khabele, MD, FACOG, FACS Assistant Professor Division of Gynecologic Oncology Vanderbilt University Medical Center Objectives 1. Review the current
More informationCervical Dysplasia and HPV
Cervical Dysplasia and HPV J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse HPV Double stranded DNA virus The HPV infect epithelial cells of the skin and mucous membranes Highest risk
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationHPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series
HPV and Cervical Cancer, Screening and Prevention John Ragsdale, MD July 12, 2018 CME Lecture Series We have come a long Way Prevalence HPV in Young Adults in U.S HPV genotypes 55-60% of All cancers 20%
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationThe prevalence of human papilloma virus in the anal region of male Chinese attendees in three public sexually transmitted disease clinics in Hong Kong
Hong Kong J. Dermatol. Venereol. (2011) 19, 6-13 Original Article The prevalence of human papilloma virus in the anal region of male Chinese attendees in three public sexually transmitted disease clinics
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationINTRODUCTION HUMAN PAPILLOMAVIRUS
INTRODUCTION HUMAN PAPILLOMAVIRUS Professor Anna-Lise Williamson Institute of Infectious Disease and Molecular Medicine, University of Cape Town National Health Laboratory Service, Groote Schuur Hospital
More informationTo further assess abnormalities detected on cervical cytological sample. To guide colposcopically directed biopsy
1 To further assess abnormalities detected on cervical cytological sample To guide colposcopically directed biopsy To exclude invasive disease To aid in outpatient management and treatment of precancerous
More informationCytology Update M Laing QEUH
Cytology Update M Laing QEUH Age change to 25 to 65 Age 25 to 50 Three yearly smear invitation Age 50 to 65 Five yearly smear invitation Women on non routine screening will be invited up to age 70 OUTCOME
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationThese comments are an attempt to summarise the discussions at the manuscript meeting. They are not an exact transcript.
Dear dr. Weber, We would like to thank you for the review of our manuscript entitled Cervical screening with an interval beyond five years requires different rescreen times for HPV-negative and HPVpositive,
More informationAcceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index
DOI 10.1007/s00404-012-2569-y GYNECOLOGIC ONCOLOGY Acceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index Hadi Shojaei Fariba Yarandi Leila
More informationPrevalence of Human Papillomavirus Genotypes in Routine Pap Smear of 2,562 Korean Women Determined by PCR-DNA Sequencing
Journal of Bacteriology and Virology 2009. Vol. 39, No. 4 p.337 344 DOI 10.4167/jbv.2009.39.4.337 Original Article Prevalence of Human Papillomavirus Genotypes in Routine Pap Smear of 2,562 Korean Women
More informationChapter 5. M.G. Dijkstra L. Rozendaal M. van Zummeren F.J. van Kemenade P.J.F. Snijders C.J.L.M. Meijer J. Berkhof. Submitted for publication
Chapter 5 CIN3 and cancer risks after primary HPV DNA testing and cytology triage in cervical cancer screening: fifteen years follow-up of a randomized controlled trial M.G. Dijkstra L. Rozendaal M. van
More informationWHAT IS CERVICAL CANCER? Presented by Dr. Sylvia Deganus
WHAT IS CERVICAL CANCER? Presented by Dr. Sylvia Deganus The Presentation What is Cancer What and where is the Cervix What causes cervical Cancer How serious is the problem of cervical cancer in Ghana?
More informationHPV-related papillomatous-condylomatous lesions in female anogenital area
HPV-related papillomatous-condylomatous lesions in female anogenital area Theo Panoskaltsis MD, FRCOG, CCST (UK) Epidemiology Anal cancer is increasing in both men and women Groups at risk: - HIV (+)
More informationChapter 2: Disease Burden and Cervical Screening in Ontario
Chapter 2: Disease Burden and Cervical Screening in Ontario Learning Objectives On completion of this section, the learner will be able to: 1. Understand human papillomavirus, disease burden, cervical
More informationMethods for HPV Detection: Polymerase Chain Reaction Assays
Monsonego J (ed): Emerging Issues on HPV Infections: From Science to Practice. Basel, Karger, 2006, pp 63 72 Methods for HPV Detection: Polymerase Chain Reaction Assays Suzanne M. Garland a,b, Sepehr Tabrizi
More informationDetection and estimation of human papillomavirus viral load in patients with cervical lesions
Bangladesh Med Res Counc Bull 2013; 39: 86-90 Detection and estimation of human papillomavirus viral load in patients with cervical lesions Rahman T 1, Tabassum S 2, Jahan M 2, Nessa A 2, Ashrafunnessa
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationBiomarkers and HPV testing: The future of cervical screening
THE FUTURE OF CERVICAL SCREENING Earn 3 CPD Points online Biomarkers and HPV testing: The future of cervical screening Professor John O Leary Associate Professor and Director of Pathology Coombe Women
More informationSCCPS Scientific Committee Position Paper on HPV Vaccination
SCCPS Scientific Committee Position Paper on HPV Vaccination Adapted from Joint Statement (March 2011) of the: Obstetrical & Gynaecological Society of Singapore (OGSS) Society for Colposcopy and Cervical
More informationHuman papiloma virus testing in the cervix of high-risk women: A hospital-based clinicopathological, colposcopic, and cytogenetic study
Research Article Human papiloma virus testing in the cervix of high-risk women: A hospital-based clinicopathological, colposcopic, and cytogenetic study Subhash Bhardwaj 1, Farooq Ahmed Wani 2, Altaf Bandy
More informationPersistence of Genital Human Papillomavirus Infection in a Long-Term Follow-Up Study of Female University Students
MAJOR ARTICLE Persistence of Genital Human Papillomavirus Infection in a Long-Term Follow-Up Study of Female University Students Laura K. Sycuro, 1,4 Long Fu Xi, 1 James P. Hughes, 2 Qinghua Feng, 3 Rachel
More informationColposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
More informationArticles. Funding Zorg Onderzoek Nederland (Netherlands Organisation for Health Research and Development).
Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASAM randomised controlled trial Dorien Rijkaart, Johannes Berkhof, Lawrence
More informationCervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix
DOI:10.31557/APJCP.2019.20.2.377 Cervical Screening Results Leading to Detecting Cervical AIS RESEARCH ARTICLE Editorial Process: Submission:09/27/2018 Acceptance:01/18/2019 Cervical Screening Results
More information